GSK 2636771

Drug Profile

GSK 2636771

Alternative Names: GSK2636771

Latest Information Update: 26 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator GlaxoSmithKline
  • Developer GlaxoSmithKline; Yonsei University Health System
  • Class Antineoplastics; Benzimidazoles
  • Mechanism of Action Phosphatidylinositol 3 kinase beta inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Gastric cancer; Malignant melanoma; Solid tumours
  • Phase I Prostate cancer

Most Recent Events

  • 17 Jul 2017 Phase-I/II clinical trials in Malignant melanoma (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater, Inoperable/Unresectable) in USA (PO) (NCT03131908)
  • 03 May 2017 M.D. Anderson Cancer Center plans a phase I/II trial for Malignant melanoma (Metastatic disease, Combination therapy, Inoperable/Unresectable, Late-stage disease, Second-line therapy or greater) in USA (NCT03131908)
  • 15 Dec 2016 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top